Literature DB >> 19851169

F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level.

Francesco Bertagna1, Giovanni Bosio, Giorgio Biasiotto, Carlo Rodella, Erinda Puta, Sara Gabanelli, Silvia Lucchini, Giuseppe Merli, Giordano Savelli, Raffaele Giubbini, Joshua Rosenbaum, Abass Alavi.   

Abstract

PURPOSE: The aim was to evaluate the incremental diagnostic rate of F-18 fluoro-fluorodeoxygulose positron emission tomography/computed tomography (F-18 FDG-PET/CT) in patients with negative I-131 whole body scans and high Tg levels. The secondary end points were correlations between F-18 FDG-PET/CT positive results and Tg levels and comparison between F-18 FDG-PET/CT accuracy in patients "on-therapy" with suppressed thyroid stimulating hormone (TSH) and those with high TSH levels.
METHODS: We studied 52 patients who had undergone total thyroidectomy and remnant ablation; they had high Tg levels (average = 156 ng/mL; SD +/- 274) after 3 weeks of levothyroxine withdrawal and negative I-131 total body scans after therapeutic doses.
RESULTS: We noted a statistically significant positive correlation between F-18 FDG-PET/CT positive results and Tg levels, irrespective of levothyroxine therapy regimen. Tg levels between F-18 FDG-PET/CT positive/negative groups were significantly different and we did not note any statistically significant correlation between F-18 FDG-PET/CT results and TSH levels, tumor size, and combination of Tg/TSH levels.
CONCLUSIONS: Our results indicate that F-18 FDG-PET/CT is a useful diagnostic tool in patients with differentiated thyroid carcinoma and with negative I-131 total body scans and high Tg levels. The levothyroxine therapy regimen does not influence F-18 FDG-PET/CT results and the rate of F-18 FDG-PET/CT positive results appears to correlate with the Tg levels. The highest accuracy is reached when the study is performed for patients with Tg levels higher than 21 ng/mL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19851169     DOI: 10.1097/RLU.0b013e3181b7d95c

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  18 in total

1.  Therapeutic impact of (18)F-FDG PET/CT in recurrent differentiated thyroid carcinoma.

Authors:  Fabio Pomerri; Anna Rita Cervino; Faise Al Bunni; Laura Evangelista; Pier Carlo Muzzio
Journal:  Radiol Med       Date:  2013-11-26       Impact factor: 3.469

2.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody.

Authors:  Su Jung Choi; Kyung Pyo Jung; Sun Seong Lee; Yun Soo Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2015-10-22

3.  99mTc-MIBI imaging in thyroid nodules: is it useful?

Authors:  Raffaele Giubbini; Francesco Bertagna
Journal:  Endocrine       Date:  2014-02-28       Impact factor: 3.633

4.  Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.

Authors:  R J D Prestwich; S Viner; G Gerrard; C N Patel; A F Scarsbrook
Journal:  Br J Radiol       Date:  2012-10       Impact factor: 3.039

Review 5.  Role of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative ¹³¹I scan: review of the literature.

Authors:  Francesco Bertagna; Giorgio Biasiotto; Emanuela Orlando; Giovanni Bosio; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

6.  Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma.

Authors:  Luca Giovanella; Pierpaolo Trimboli; Frederik A Verburg; Giorgio Treglia; Arnoldo Piccardo; Luca Foppiani; Luca Ceriani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-06       Impact factor: 9.236

7.  [18F]-FDG-PET/CT and [18F]-FAZA-PET/CT Hypoxia Imaging of Metastatic Thyroid Cancer: Association with Short-Term Progression After Radioiodine Therapy.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Atsushi Tani; Yoriko Kajiya; Tooru Nandate; Ikumi Kitazano; Takashi Yoshiura
Journal:  Mol Imaging Biol       Date:  2020-12       Impact factor: 3.488

8.  Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India.

Authors:  Shoukat Hussain Khan; Masood Ul Hassan; Rajesh Singh Bhau
Journal:  Indian J Nucl Med       Date:  2015 Jul-Sep

9.  Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.

Authors:  Jandee Lee; Kuk Young Nah; Ra Mi Kim; Yeon-Ju Oh; Young-Sil An; Joon-Kee Yoon; Gwang Il An; Tae Hyun Choi; Gi Jeong Cheon; Euy-Young Soh; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

10.  Usefulness of PET/CT in the diagnosis of recurrent or metastasized differentiated thyroid carcinoma.

Authors:  Cun-Zhi Lu; Su-Sheng Cao; Wei Wang; Jun Liu; Ning Fu; Feng Lu
Journal:  Oncol Lett       Date:  2016-02-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.